Forward Therapeutics Welcomes New Chief Medical Officer
Forward Therapeutics, Inc., a pioneering biopharmaceutical company dedicated to transforming treatments for chronic inflammatory disorders, has strengthened its leadership team with a significant new appointment. The company has named Dr. Ulrich Thienel, M.D., Ph.D., as its Chief Medical Officer, a crucial move that aligns with its ambitious clinical goals.
Dr. Ulrich Thienel's Role at Forward Therapeutics
In his new role, Dr. Thienel will spearhead the development of Forward's clinical programs across multiple regions, ensuring effective operations and progress in research initiatives. His extensive experience and expertise in immunology will be vital as the company strives to create next-generation therapies.
Vision for the Future
“We are excited to welcome Ulrich to our team,” stated Toufike Kanouni, CEO and co-founder of Forward Therapeutics. “His impressive background in both biotech and large pharmaceutical companies is perfectly aligned with our strategic objectives.”
Innovation in Immunology
With over twenty years of experience, Dr. Thienel possesses a deep understanding of autoimmune diseases, hematology, respiratory conditions, and rare disorders. His career features key positions at prestigious companies such as Finch Therapeutics, Johnson & Johnson, and Takeda Pharmaceuticals, where he was instrumental in the research, development, and commercialization of groundbreaking therapies.
Dr. Thienel's Noteworthy Background
Dr. Thienel earned his M.D. and Ph.D. from Justus-Liebig University in Giessen, Germany. He further honed his skills with a specialty in Rheumatology at Columbia University and completed Executive Training at Northwestern University. His unique blend of medical and business expertise equips him to effectively lead Forward Therapeutics toward success.
Commitment to Therapeutic Advancement
“Joining Forward Therapeutics represents an exciting opportunity,” Dr. Thienel remarked. “Their innovative platform of oral immunomodulators has the potential to offer new solutions for patients suffering from chronic inflammatory conditions.”
About Forward Therapeutics, Inc.
Forward Therapeutics is committed to reshaping the treatment landscape for chronic inflammatory disorders. The company is developing a series of next-generation small molecule immune therapies. Recently, Forward successfully raised $50 million in a financing round, reflecting the strong confidence investors have in its future. For more details, visit www.forward-tx.com or follow the company on LinkedIn.
Contact Information
For further inquiries, please reach out to Toufike Kanouni at (561) 232-2641 or via email at [email protected].
Frequently Asked Questions
Who is the new Chief Medical Officer of Forward Therapeutics?
Dr. Ulrich Thienel, M.D., Ph.D. has been appointed as the Chief Medical Officer at Forward Therapeutics.
What will Dr. Thienel's role be at the company?
Dr. Thienel will oversee Forward's clinical programs and development efforts, guiding operations in the U.S. and internationally.
What experience does Dr. Thienel bring?
Dr. Thienel has over 20 years of experience in immunology, with significant roles in both large pharmaceutical and biotech companies.
What is Forward Therapeutics known for?
Forward Therapeutics focuses on developing innovative treatments for chronic inflammatory disorders via next-generation therapies.
How can I learn more about Forward Therapeutics?
To learn more, visit their website at www.forward-tx.com.